139 results on '"Perno, Carlo F"'
Search Results
2. Pancreatic Stone Protein in the Diagnosis of Sepsis in Children Admitted to HighDependency Care: A Single-Center Prospective Cohort Study.
3. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
4. Current and future challenges in HCV: insights from an Italian experts panel
5. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study
6. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
7. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe
8. CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases
9. Secondary Mutations in the Protease Region of Human Immunodeficiency Virus and Virologic Failure in Drug-Naive Patients Treated with Protease Inhibitor-Based Therapy
10. Impact of HIV-1 tropism on the emergence of non-AIDS events in HIV-infected patients receiving fully suppressive antiretroviral therapy
11. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy
12. Prevalence and Outcome of Patients with Acute Myocarditis and Positive Viral Search on Nasopharyngeal Swab
13. Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab
14. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
15. Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats
16. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon
17. Safe use of the icteric index as possible diagnostic algorithm in the determination of bilirubin
18. Methotrexate inhibits SARS‐CoV‐2 virus replication “in vitro”
19. Influence of glomerular function on values of cardiac troponin T in patients with suspected acute coronary syndrome
20. Implementing anti-retroviral triple therapy to prevent HIV mother-to-child transmission: a public health approach in resource-limited settings
21. HIV-1-Associated Dementia During HAART Therapy
22. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
23. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients
24. Is total lymphocyte count a reliable predictor of the CD4 lymphocyte cell count in resource-limited settings?
25. Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy
26. Secondary mutations in the protease region of Human Immunodeficiency Virus and virologic failure in drug-naive patients treated with protease inhibitor--based therapy
27. HCV resistance compartmentalization within tumoral and non‐tumoral liver in transplanted patients with hepatocellular carcinoma
28. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen
29. Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants
30. Combined evaluation of genotype and phenotype of thiopurine S-methyltransferase (TPMT) in the clinical management of patients in chronic therapy with azathioprine
31. Methotrexate inhibits SARS‐CoV‐2 virus replication "in vitro".
32. Corrigendum to “Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018” [Drug Resist. Updates 37 (March) (2018) 17–39]
33. Current and future challenges in HCV: insights from an Italian experts panel
34. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
35. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
36. Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease
37. A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based Therapy
38. Circulation of HIV-1 CRF02_AG among MSM Population in Central Italy: A Molecular Epidemiology-Based Study
39. Treatment-experienced patients: salvage interventions and switch strategies
40. Improving the Prediction of Virological Response to Tipranavir: The Development and Validation of a Tipranavir-Weighted Mutation Score
41. Cross-Resistance among Nonnucleoside Reverse Transcriptase Inhibitors Limits Recycling Efavirenz after Nevirapine Failure
42. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofoviremtricitabinelamivudineefavirenz administered on a multiple tablet therapy
43. Implications of HIV Drug Resistance on First- and Second-Line Therapies in Resource-Limited Settings: Report from a Workshop Organized by the Collaborative HIV and Anti-HIV Drug Resistance Network
44. Interpretation of Genotypic HIV-1 Resistance to Darunavir and Virological Response: Validation of Available Systems and of a New Score
45. Historical resistance profile helps to predict salvage failure
46. Use of novel antiretroviral agents in rescue regimens: A case of early virological failure to raltegravir.
47. Preparation and Characterization of an Intravenous Solution of IgG From Human Immunodeficiency Virus-Seropositive Donors
48. Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease
49. Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
50. Natural NS3, NS5A and NS5B HCV resistance is common in real practice, differently associated to HCV genotypes and response to NS5A inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.